000291980 001__ 291980
000291980 005__ 20250218125235.0
000291980 0247_ $$2doi$$a10.1038/s41591-024-03143-y
000291980 0247_ $$2pmid$$apmid:39054374
000291980 0247_ $$2ISSN$$a1078-8956
000291980 0247_ $$2ISSN$$a1546-170X
000291980 0247_ $$2altmetric$$aaltmetric:165675369
000291980 037__ $$aDKFZ-2024-01563
000291980 041__ $$aEnglish
000291980 082__ $$a610
000291980 1001_ $$0P:(DE-HGF)0$$aHiensch, Anouk E$$b0$$eFirst author
000291980 245__ $$aSupervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial.
000291980 260__ $$aNew York, NY$$bNature America Inc.$$c2024
000291980 3367_ $$2DRIVER$$aarticle
000291980 3367_ $$2DataCite$$aOutput Types/Journal article
000291980 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730202495_22133
000291980 3367_ $$2BibTeX$$aARTICLE
000291980 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291980 3367_ $$00$$2EndNote$$aJournal Article
000291980 500__ $$a#EA:C110# / 2024 Oct;30(10):2957-2966
000291980 520__ $$aPhysical exercise both during and after curative cancer treatment has been shown to reduce side effects. Evidence in the metastatic cancer setting is scarce, and interventions that improve health-related quality of life (HRQOL) are much needed for patients with metastatic breast cancer (MBC). The multinational randomized controlled PREFERABLE-EFFECT trial assessed the effects of exercise on fatigue and HRQOL in patients with MBC. In total, 357 patients with MBC and a life expectancy of ≥6 months but without unstable bone metastases were recruited at eight study centers across five European countries and Australia. Participants were randomly assigned (1:1) to usual care (control group, n = 179) or a 9-month supervised exercise program (exercise group, n = 178). Intervention effects on physical fatigue (European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-FA12 scale) and HRQOL (EORTC QLQ-C30 summary score) were determined by comparing the change from baseline to 3, 6 (primary timepoint) and 9 months between groups using mixed models for repeated measures, adjusted for baseline values of the outcome, line of treatment (first or second versus third or higher) and study center. Exercise resulted in significant positive effects on both primary outcomes. Physical fatigue was significantly lower (-5.3 (95% confidence interval (CI), -10.0 to -0.6), Bonferroni-Holm-adjusted P = 0.027; Cohen's effect size, 0.22) and HRQOL significantly higher (4.8 (95% CI, 2.2-7.4), Bonferroni-Holm-adjusted P = 0.0003; effect size, 0.33) in the exercise group than in the control group at 6 months. Two serious adverse events occurred (that is, fractures), but both were not related to bone metastases. These results demonstrate that supervised exercise has positive effects on physical fatigue and HRQOL in patients with MBC and should be recommended as part of supportive care.ClinicalTrials.gov Identifier: NCT04120298 .
000291980 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000291980 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291980 7001_ $$0P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5$$aDepenbusch, Johanna$$b1$$eFirst author$$udkfz
000291980 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b2$$udkfz
000291980 7001_ $$aMonninkhof, Evelyn M$$b3
000291980 7001_ $$aPelaez, Mireia$$b4
000291980 7001_ $$aClauss, Dorothea$$b5
000291980 7001_ $$00009-0008-5847-7086$$aGunasekara, Nadira$$b6
000291980 7001_ $$aZimmer, Philipp$$b7
000291980 7001_ $$aBelloso, Jon$$b8
000291980 7001_ $$aTrevaskis, Mark$$b9
000291980 7001_ $$00000-0002-5617-9076$$aRundqvist, Helene$$b10
000291980 7001_ $$aWiskemann, Joachim$$b11
000291980 7001_ $$aMüller, Jana$$b12
000291980 7001_ $$00000-0003-4892-4061$$aSweegers, Maike G$$b13
000291980 7001_ $$0P:(DE-He78)eab4414b2d1a38e0c27a03e1483409bd$$aFremd, Carlo$$b14
000291980 7001_ $$aAltena, Renske$$b15
000291980 7001_ $$aGorecki, Maciej$$b16
000291980 7001_ $$aBijlsma, Rhodé$$b17
000291980 7001_ $$avan Leeuwen-Snoeks, Lobke$$b18
000291980 7001_ $$aTen Bokkel Huinink, Daan$$b19
000291980 7001_ $$00000-0001-8088-9628$$aSonke, Gabe$$b20
000291980 7001_ $$aLahuerta, Ainhara$$b21
000291980 7001_ $$aMann, G Bruce$$b22
000291980 7001_ $$00000-0002-7207-9286$$aFrancis, Prudence A$$b23
000291980 7001_ $$aRichardson, Gary$$b24
000291980 7001_ $$aMalter, Wolfram$$b25
000291980 7001_ $$avan der Wall, Elsken$$b26
000291980 7001_ $$aAaronson, Neil K$$b27
000291980 7001_ $$00000-0001-6855-397X$$aSenkus, Elzbieta$$b28
000291980 7001_ $$aUrruticoechea, Ander$$b29
000291980 7001_ $$aZopf, Eva M$$b30
000291980 7001_ $$aBloch, Wilhelm$$b31
000291980 7001_ $$aStuiver, Martijn M$$b32
000291980 7001_ $$00000-0001-8317-7829$$aWengstrom, Yvonne$$b33
000291980 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b34$$udkfz
000291980 7001_ $$00000-0003-0643-3790$$aMay, Anne M$$b35
000291980 773__ $$0PERI:(DE-600)1484517-9$$a10.1038/s41591-024-03143-y$$n10$$p2957-2966$$tNature medicine$$v30$$x1078-8956$$y2024
000291980 8564_ $$uhttps://inrepo02.dkfz.de/record/291980/files/s41591-024-03143-y.pdf
000291980 8564_ $$uhttps://inrepo02.dkfz.de/record/291980/files/s41591-024-03143-y.pdf?subformat=pdfa$$xpdfa
000291980 909CO $$ooai:inrepo02.dkfz.de:291980$$pVDB
000291980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000291980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000291980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eab4414b2d1a38e0c27a03e1483409bd$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000291980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000291980 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000291980 9141_ $$y2024
000291980 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-29$$wger
000291980 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2023-08-29$$wger
000291980 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT MED : 2022$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-29
000291980 915__ $$0StatID:(DE-HGF)9980$$2StatID$$aIF >= 80$$bNAT MED : 2022$$d2023-08-29
000291980 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000291980 9200_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000291980 980__ $$ajournal
000291980 980__ $$aVDB
000291980 980__ $$aI:(DE-He78)C110-20160331
000291980 980__ $$aUNRESTRICTED